Analysts Maintain Buy Ratings on Vir Biotechnology Despite Widening Losses
核心洞察
Evercore ISI (搜索) analyst Cory Kasimov reiterated a Buy rating on Vir Biotechnology with a $22.00 price target, citing the company's healthcare sector potential.
Barclays (搜索) analyst Etzer Darout also maintained a Buy rating with a more bullish $30.00 price target, reflecting continued confidence in the firm's pipeline.
Vir Biotechnology reported a GAAP net loss of $125.7 million for the quarter ending March 31, compared to a $120.97 million loss in the same period last year.
Wall Street analysts remain bullish on Vir Biotechnology despite the company's widening quarterly losses, with two major firms reiterating Buy ratings in recent reports.
Evercore ISI (搜索) analyst Cory Kasimov, a 5-star analyst with a 19.4% average return and 60.08% success rate according to TipRanks, maintained a Buy rating on Vir Biotechnology with a price target of $22.00. Kasimov covers the Healthcare sector, focusing on stocks including Vertex Pharmaceuticals, Vir Biotechnology, and Beam Therapeutics.
In a separate report, Barclays (搜索) analyst Etzer Darout also maintained a Buy rating on the stock, setting a more optimistic price target of $30.00. Darout, who covers Incyte, BeOne Medicines, and Abivax SA Sponsored ADR in the Healthcare sector, has an average return of 29.4% and a 60.00% success rate on recommended stocks, per TipRanks data.
The analyst consensus for Vir Biotechnology stands at Strong Buy, with a consensus price target of $21.50.
These endorsements come as Vir Biotechnology reported a quarterly GAAP net loss of $125.7 million for the quarter ending March 31. This compares to a GAAP net loss of $120.97 million in the same period last year, when the company posted revenue of $3.03 million. The widening loss underscores the financial challenges facing the biotechnology firm as it continues to invest in its development pipeline.
The sustained analyst confidence suggests that Wall Street views the company's long-term prospects favorably, looking beyond near-term financial headwinds to the potential value of Vir Biotechnology's research and development programs.